A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

What is the purpose of this trial?

The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care.



Actinium Pharmaceuticals Inc.

Start Date: 07/17/2017

End Date: 06/01/2019

Last Updated: 02/22/2018

Study HIC#: 1607018056

Get Involved

For more information about this study, contact:
Tanya Malak
+1 203-785-4699
tanya.malak@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image